AstraZeneca
NEWS
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
It was another busy week for clinical trial updates. Here’s a look.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregivers living with liver cancer.
In addition to various deal news, AstraZeneca had clinical trial news today as well.
That would accelerate the company’s “decarbonization” plan by more than a decade.
AstraZeneca’s Imfinzi (durvalumab) and tremelimumab were granted Orphan Drug designation by the U.S. Food and Drug Administration as a possible treatment for hepatocellular carcinoma.
There were plenty of clinical trial announcements this week. Here’s a look.
AstraZeneca announced that after a recommendation from an independent Data Monitoring Committee, it was abandoning its Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) for mixed dyslipidemia (MDL).
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
JOBS
IN THE PRESS